NEW YORK, Jan 25 – Structural Bioinformatics said Thursday that it had reached a deal to “elucidate” protein structures for The RW Johnson Pharmaceutical Research Institute, a subsidiary of Johnson & Johnson.
“We are extremely pleased to begin a relationship with The R.W. Johnson
Pharmaceutical Research Institute on target structure elucidation,” Edward Maggio, CEO of SBI, said in a statement.
SBI did not disclose financial details or say what targets SBI would work on. The company could not immediately be reached for comment.
In the statement, SBI said it would provide RW Johnson with access to SBI's x-ray crystallography program for “several” undisclosed targets in its drug discovery efforts. Details about SBI’s x-ray crystallography program could not immediately be ascertained. In the past, the company has tended to downplay the need to use x-ray crystallography, focusing attention on its ability to generate protein structures in silico .
SBI is a privately held company based in San Diego.